COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #205 of 257
12/4 Late treatment study
Ozturk et al., Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa271 (Peer Reviewed)
Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey
Source   PDF   Share   Tweet
Retrospective 1210 hospitalized patients in Turkey focused on chronic kidney disease, haemodialysis and renal transplant patients, but also showing lower mortality with HCQ. Subject to confounding by indication.

Ozturk et al., 12/4/2020, retrospective, Turkey, Middle East, peer-reviewed, 70 authors.
risk of death, 43.9% lower, RR 0.56, p = 0.14, treatment 165 of 1127 (14.6%), control 6 of 23 (26.1%), CQ/HCQ.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 257 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit